Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

NCT04165993 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Concurrent chemotherapy and KN026
DRUG: KN026 monotherapy
DRUG: KN026 combination

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd